Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salvia miltiorrhiza polyphenolic acid is a purified botanical extract derived from the root of *Salvia miltiorrhiza* (Danshen), a traditional Chinese medicinal herb. It is primarily composed of water-soluble polyphenolic compounds, with salvianolic acid B serving as the major active constituent. The drug is approved in China for the treatment of acute ischemic stroke and cerebral infarction. Its therapeutic mechanism involves neuroprotection through the inhibition of oxidative stress, reduction of pro-inflammatory cytokine production (such as TNF-alpha and IL-6), and prevention of neuronal apoptosis. Additionally, it has been shown to improve cerebral microcirculation and maintain blood-brain barrier integrity following ischemic injury. It is typically administered via intravenous infusion in clinical settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salvia miltiorrhiza polyphenolic acid.